31 August 2018
A new report by visiongain forecasts that overall pharmaceutical contract manufacturing market will achieve revenues of $84.0 billion in 2020, at a compound annual growth rate of 6.4% from 2015 to 2020. The market is expected to continue to grow from 2016 to 2026 as the pharmaceutical companies are strategically outsourcing services. That revenue prediction and others appear in Pharma Leader Series: Leading Pharmaceutical Contract Manufacturing Organisations (CMOs) 2016-2026.
Visiongain is a business information publisher and consultancy in London, UK. Its purpose is to help organisations understand commercial prospects of industries and markets in healthcare and other fields.
This updated study discusses market-leading companies, the strategies they have employed to grow in the past few years, and how they will continue to expand to 2026. The study analyses deals, commercial prospects and financial performances of 30 leading pharmaceutical CMOs in the following regions:
• North America
In particular it discusses revenue prospects, including forecasts, analysis of the operational performance and forecast profitability of some leading CMOs. The new investigation also discusses forces driving and restraining individual firms and provides competitive intelligence for companies operating in the pharmaceutical contract manufacturing market. It also examines opportunities and challenges for individual firms and strategies that can be employed to maximise performance from 2016 to 2026.
In 2015, out of all the contract manufacturing services, API Manufacturing continues to hold the largest share of the total market revenue like last year. In parallel, FDF manufacturing shows the fastest growth. Geographically, developed countries hold the maximum share of the outsourcing. North America holds the largest market share of the industry. This study shows that pharmaceutical companies will continue to outsource mainly in developed countries. However, the Indian and Chinese markets are growing at a faster rate as compared to the CMO market in developed countries.
Shruti Tayal, a pharmaceutical industry analyst at visiongain said: “Within pharmaceutical contract manufacturing, active pharmaceutical ingredient (API) continues to form the largest revenue producing segment in 2015. Final dosage form (FDF) continues to expand at the fastest rate from 2016 to 2026. Leading CMOs will capture most of the customers owing to integrated service offerings, also benefiting from consolidation in that pharma service industry. Pharmaceutical companies will continue to outsource some manufacturing operations to save time and money in emerging regions such as India, China and Latin America. Those firms will increase competition in the developing national CMO markets. India and China are already prominent for contract production of APIs and FDFs for domestic use and export. That trend will continue, with opportunities also remaining for CMO operations in North America, Europe, Japan and other established markets, especially for high-value biological drug products”.
Visiongain’s new investigation identifies main trends and revenue predictions at overall world market and individual company level.
This report discusses company profiles, recent mergers and acquisitions and analysis of the company’s recent financial performance. A SWOT analysis and forecast for all 5 firms, in the period of 2016-2026.
- The leading CMOs in North America:
- The leading CMOs in Europe:
• Evonik Degussa
• Royal DSM
• Boehringer Ingelheim
• Corden Pharma
- The leading CMOs in Japan:
- 3 leading API specialists:
• Teva API
• Esteve Quimica
- China’s 3 leading CMOs:
• Zhejiang Hisun Pharmaceuticals
• Zhejiang Huahai Pharmaceuticals
• Shandong Xinhua Pharmaceuticals
- Indian’s 3 leading CMOs:
• Aurobindo Pharma
• Divis Laboratories
• Dr. Reddy’s Laboratories
Top 30 Pharmaceutical Contract Manufacturing Organisations (CMOs) – Market, Industry, Trends, Technologies and Prospects 2016-2026 adds to visiongain’s analytical reports on industries and markets in healthcare. Together those studies cover pharmaceuticals, medical devices, diagnostics, national markets, biotechnologies and outsourced services.
As lockdowns were imposed in all the countries, diagnosis rates went down in majority of countries during the year hitting the drug sales for some period. Although lockdown measures have been eased up in most countries by mid-year 2020, this trend is expected to continue beyond 2020, stock up of medicines by patients is likely to propel the drug sales in majority of the developed economies, which account for majority of rare diseases.
02 March 2021
Product approval is a major milestone facing all key competitors in the respiratory inhalers market. Several strategies were implemented by key market players between 2015 and Jan 2021.
26 February 2021
The global bile duct cancer drug market has been growing considerably owing to the rising incidence and prevalence rate of bile duct cancer patients worldwide, technological advancement in drug development, and healthcare spending.
22 February 2021
The global Big Data Analytics in Healthcare market has been growing considerably owing to the rising technological advancement, growing investment, and cohesive government policies.